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Abstract  
Cerebral ischemia is known to be a major cause of death and the later development of 
Alzheimer’s disease and vascular dementia. However, ischemia induced cellular damage 
that initiates these diseases remain poorly understood. This is primarily due to lack of 
clinically relevant models that are highly reproducible. Here, we have optimised a murine 
model of global cerebral ischaemia with multiple markers to determine brain pathology, 
neurochemistry and correlated memory deficits in these animals. Cerebral ischaemia in mice 
was induced by bilateral common carotid artery occlusion. Following reperfusion, the mice 
were either fixed with 4% paraformaldehyde or decapitated under anaesthesia.  Brains were 
processed for Western blotting or immunohistochemistry for glial (GLT1) and vesicular 
(VGluT1, VGluT2) glutamate transporters and paired helical filament (PHF1) tau. The PHF1 
tau is the main component of neurofibrillary tangle, which is the pathological hallmarks of 
Alzheimer’s disease and vascular dementia.  The novel object recognition behavioural assay 
was used to investigate the functional cognitive consequences in these mice. The results 
show consistent and selective neuronal and glial cell changes in the hippocampus and the 
cortex together with a significant reduction in GLT1 (***P< 0.001), VGluT1 (**P<0.01) and 
VGluT2 (***P<0.001) expression in the hippocampus in occluded mice as compared to 
sham-operated animals. These changes are associated with increased PHF1 (***P<0.0001) 
protein and a significant impairment of performance (*p<0.0006, N=6/group) in the novel 
object recognition test. This model represents a useful tool for investigating cellular, 
biochemical and molecular mechanisms of global cerebral ischaemia and may be an ideal 
preclinical model for vascular dementia.   
 
Key words: Global cerebral ischaemia; Glutamate Transporter; Tau protein; Memory deficit; 
Vascular Dementia; Glial cells; Hippocampus; Stroke  
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Introduction  
Cerebral ischaemia, which results from stroke, cardiac arrest and cardiac surgery, is one of 
the most common causes of death and disability worldwide (Flynn et al., 2008; Kim and 
Johnston 2011).  In acute ischemic stroke a blood vessel in the brain gets occluded by 
thrombosis or embolism, resulting in neuronal damage and death in an area surrounding the 
occluded vessel (focal ischaemia) whereas global cerebral ischaemia, which is caused by 
cardiac arrest and cardiac surgery, encompasses wide areas of brain tissue. The 
pathophysiology resulting from cerebral ischaemia is a leading cause of death and adult 
disability and a major risk factor for later development of various neurogenerative diseases 
including Alzheimer’s disease and vascular dementia (De la Torre, 2004a; 2004b;  Hazell, 
2007; Pluta et.al., 2013),   A significant proportion (60-90%) of Alzheimer’s disease and 
vascular dementia patients exhibit cerebrovascular pathology including cerebral infarcts and 
ischaemic lesions leading to more rapid cognitive decline in patients diagnosed with these 
diseases (Kalaria,  2000).   However, cerebral ischaemia induced cellular damage that 
initiates cerebrovascular pathology and related memory dysfunction remain poorly 
understood and this has mired the development of new drug treatment strategies. The 
possible reasons for this failure include lack of a clinically relevant model that is highly 
reproducible as the pathophysiology of cerebral ischaemia injury in animal models is 
influenced by numerous factors including the species, type of blood vessels occluded, 
occlusion period and reperfusion time (Hossmann, 1998).  
 
This study aims to optimise a murine model of global cerebral ischaemia and reperfusion 
and uses a variety of cellular and neurochemical markers to determine the extent of 
neuronal and glial cell damage and changes in glutamate transporters in the hippocampus 
and cortex, as assessed using immunohistochemistry (IHC). Changes in glutamate 
transporter proteins in the hippocampus were quantified by Western Blotting (WB). Since 
there is a strong correlation between cerebral ischaemia and the neurodegenerative 
diseases (Fujii et al., 2016; Kalaria, 2000), we have examined the expression of 
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hyperphosphorylated tau protein in the hippocampus to determine if ischemic insult in this 
model results in the development of tau pathology. Hyperphosphorylated tau is known to 
accumulate as paired helical filament (PHF) which is the main component of neurofibrillary 
tangle, one of the pathological hallmarks of many neurodegenerative diseases including 
Alzheimer’s disease and vascular dementia (Andorfer et al., 2003; Rissman and Poon 
2017). We have also assessed memory correlates of histologically and biochemically 
determined ischaemic damage in this model. Our hypothesis is that cerebral ischaemia 
induced cellular damage through alterations in glutamate transporters in the brain lead to 
neurodegenerative pathology and memory dysfunction.   
 
Materials and Methods:        
Animals 
 All experiments were performed on 10- to 12-week-old (25–30 g) male C57BL/6J mice 
(Harlan-Olac, Bicester, UK) under appropriate United Kingdom Home Office personal and 
project licenses and they adhered to the regulations as specified in the U.K. Animals 
(Scientific Procedures) Act, 1986 and associated guidelines, the European Communities 
Council Directive of 24 November 1986 (86/609/EEC). 
 
Cerebral ischaemia and reperfusion injury  
Cerebral ischaemia was induced in mice (n=48) by transient bilateral common carotid artery 
occlusion (BCCAO). In brief, under anaesthesia with isoflurane (1-1.5% in oxygen) and 
intraperitoneal injection of buprenorphine HCL (0.25 mg/ kg), both carotid arteries were 
isolated through a midline neck incision and occluded with microserrefines. Perfusion was 
restored by removing the microserrefines after a 10, 15 or 18 min occlusion period (n= 6 per 
group) and the wound was sutured and anaesthesia discontinued.  
Following surgery each mouse was injected intraperitoneally with sterile saline (0.4 ml). For 
mice in the sham operated group (n=48), the same surgical procedure was performed 
except that the common carotid arteries were not occluded. Core body temperature was 
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regulated at 37 ± 0.5°C by a warming plate throughout the procedure and after the operation 
until the mouse was recovered from anaesthesia.  Reperfusion was then allowed for 3 or 7 
days, as our pilot study showed no visible ischemic damage following a 1 or 2-day 
reperfusion.  Pilot results also indicated very little ischaemic damage following occlusion of 
carotid arteries less than 10min even after 7 days reperfusion. 
 
Assessment of neurological deficit 
Neurological assessment was performed in BCCAO and sham operated mice by 
neurological deficit signs including disturbances of consciousness, circling, torsion of the 
neck and seizure (Yang et al., 1997) i.e., 0, no observable deficit; 1, drowsiness and circling; 
2, torsion of the neck and disappearance of the righting reflex; 3, seizure; 4, no spontaneous 
movement or coma.    
 
Assessment of cerebral ischaemia injury using histochemistry and 
immunohistochemistry 
Following 3 or 7day, BCCAO and sham-operated mice were perfused transcardially with 4% 
paraformaldehyde in 0.1M phosphate buffer (PB, pH 7.4). Brains were post-fixed overnight 
and stored in PB at 4°C. Sections cut on a vibrating mi crotome (Leica Microsystems, 
Germany) were processed for either cresyl violet staining or IHC according to the methods 
described in our previous study (Ketheeswaranathan et al., 2011). Antibodies details and 
dilutions used for IHC are listed in table 1.  
 
Antibody specificity 
Antibodies against GLAST (A522) and GLT1 (B12) were prepared by immunising rabbits 
with C terminal peptide A522–541 (PYQLIAQDNEPEKPVADSET) or N-terminal peptide 12–
26 (KVEVRMHDSHLSSE), respectively. These antibodies were raised, purified and 
extensively characterised as previously described (Lehre and Danbolt 1998 ; Lehre KP et 
al., 1995).  The specificity of polyclonal rabbit antisera raised against VGLUT1 and VGLUT2 
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and mouse monoclonal antibodies raised against PHF1 were also extensively tested 
previously [VGLUT1 and -2, (Varoqui et al., 2002) ; PHF1 Tau (Andorfer et al., 2003).  
 
Analysis of histochemical and immunohistochemical data  
Cresyl violet stained or immunostained sections were viewed on an AxioImager Z.1 
epifluorescence microscope (Carl Zeiss, Welwyn Garden City, UK). Bright field images were 
captured using a Zeiss AxioVision Imaging System. All images were imported into Adobe 
Photoshop 7.0 for minor adjustment of brightness and contrast, resizing or cropping and 
assembling into figures. After lettering, the layers were merged, resolution was adjusted to 
500 dpi and the images were saved as TIFF files. 
 
Stereological method for quantification of immunolabelled profiles 
The number of NeuN immunoreactive (-IR) neuronal cells and GFAP-IR glial cells per unit 
volume of tissue in defined brain areas was estimated using a three-dimensional counting 
method based on the well-established optical dissector method (Williams and Rakie 1988). 
Areas of the hippocampus and cortical region to be sampled were located by examining 
immunolabelled sections under bright field light illumination at low magnification (10 
objectives). Because most of the mice in our study showed hippocampal and cortical 
damage in both hemispheres, histological analysis was conducted unilaterally. Analysis was 
performed at two levels of sectioning from each brain: interaural line (2.34mm to 1.74mm); 
bregma (1.54mm to 2.06 mm). Images were captured into Axiovision, using the x10 
objective. Each captured image corresponded to an area of tissue measuring 450 x 350 um. 
An acetate sheet with standard unbiased counting frame (Gundersen, 1977), each side 
equivalent to 200 um at this magnification, was laid over the image on the monitor, to form a 
counting box for the image. All immunopositive cells falling within the counting frame were 
marked on the image using the ‘event counting’ facility of the measurement module, and the 
images were examined to ensure that each cell ⁄ nucleus was counted only once. All counts 
were performed blindly on coded slides by a single observer. Data were analysed using one-
 ACCEPTED MANUSCRIPT
 
7 
way ANOVA to determine statistical significance and multiple comparison test was used for 
post-hoc comparisons. P < 0.05 was considered statistically significant. 
 
Tissue preparation for Western Blotting  
Western blotting analysis were performed on tissue samples from hippocampal regions only. 
Foo this the mice were killed by decapitation under anaesthesia, brains removed and rapidly 
frozen on dry ice. Coronal slices of approximately 1mm thickness were cut from the 
forebrain (over dry ice) with a scalpel blade and then hippocampal tissue samples (25-35 
mg) from both sides of the brain were collected at the level of the forebrain corresponding to 
bregma −0.22 to −2.06mm (Paxinos and Franklin 2014) with 1mm corer under a ×5 
dissecting microscope. 
 
Protein extraction  
The brain tissue was homogenised using a blunt 20-gauge blunt needle and protein was 
extracted using SDS-PAGE sample buffer (Tris 500 mM, PH 6.8, glycerol, 100 mM EDTA 
and 2% SDS). Samples containing total protein were mixed with an equal volume of SDS 
dissociation buffer (900µl SDS, 100µl beta mecracaptoethanol, 10µl Bromophenol blue 
solutions) and boiled for 5 min. Protein concentration in samples was measured using the 
standard BCA method. 
 
Western Blotting     
Proteins were resolved by SDS polyacrylamide gel electrophoresis using 10% 
polyacrylamide gels. Resolved proteins were transferred to Polyvinylidene difluoride 
membrane (Amersham, GE Healthcare, UK). The membrane was blocked for 1 hr with PBS 
containing 0.1% (v/v) Tween-20 and 5% (w/v) dried milk powder and incubated at 4o C 
overnight in primary antibodies against GLT1 (1/3000), VGLUT1 (1/1000), VGLUT2 (1/2000) 
and PHF1 (1/1000) diluted in PBS- Tween containing 2% (w/v) bovine serum albumin. 
Horseradish peroxidase-conjugated secondary antibodies, either anti-rabbit or anti-mouse 
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IgG were used at 1:4000 dilution in PBS-Tween containing 2% (w/v) BSA. Bound antibodies 
were detected using the enhanced chemiluminescence detection system (Amersham 
Biosciences, Amersham, UK) and visualised using a Las-3000 Fujifilm imager. 
Densitometric analysis of blots was performed using image- J software. Data are shown as 
mean ± SEM, p<0.001  
 
Training and assessment in novel object recognition test 
Both sham and occluded mice were housed in groups of two. On the day of testing the 
animals were transferred from the holding room to the room adjacent to the testing area 2 hr 
prior to testing. Testing comprised of placing animals individually into a cylindrical arena (35 
cm diameter) with black walls illuminated from above with a 40 W angle poise lamp to 
eliminate areas of shadow without creating an overtly bright arena. All animals were handled 
and habituated to the test arena (with no objects) for at least a week prior to the test to 
maximise interaction with the objects.  The objects utilised for recognition testing were of 
similar material and texture (plastic) but differed in shape. On day 1 of each experiment 
(learning phase), the animal was placed in the arena with two identical objects (Familiar: 2 x 
plastic column, 10 cm high x 2 cm wide constructed from children's building blocks) secured 
to the floor of the arena and allowed to explore the objects for 2time periods of 10 min, each 
separated by 5 min. One hour later a novel object (Novel: plastic cross shape, 10 cm x 10 
cm) again secured to the floor of the arena was substituted for one of the familiar ones and 
retention was tested by placing the animal back into the test arena for 5 min (test phase). 
The amount of time each animal spent exploring the objects was recorded by video camera 
and scored by an experimenter blind to the experimental condition (occluded vs sham) of 
each animal. Successful exploration of an object was judged by animal following clearly 
defined criteria: both forelimbs within a 15cm diameter circle of the object, head orientated 
directly at the object or physically touching the object with its nose. Scoring was completed 
by recording the time each animal investigated each object and also the general locomotion 
behaviour (the animal engaging in general ambulatory activity around the arena).  
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Differences in object interactions were assessed by calculating the discrimination ration (DR) 
= Tn/(Tn+Tf) where: Tf = Time with familiar object, Tn= Time with novel object.  Non-paired 
two-way t-tests were utilised to assess any statistical significance of DR and general 
locomotion between the experimental and sham treated control animals.  
Following completion of behavioural tests, mice were euthanized appropriately and brain 
tissue obtained from the BCCAO mice and sham controls were processed for IHC and WB 
analysis using specific antibodies as described above and any correlation between cerebral 
ischaemia induced cellular, neurochemical and behavioural changes was determined.  
 
Results: 
Cresyl violet staining 
Cresyl violet staining showed ischemic damage, as assessed by chromatolytic changes in 
the hippocampus (Figure 1A-H) and the cortex (Figure 1J-P) following 15m occlusion and 
3day or 7day reperfusion, with a very low mortality (<2%).  Cellular damage was also seen in 
the striatum and thalamus (data not shown). At 24hr reperfusion times very little evidence of 
degenerative changes was observed. Similarly, 10 min ischaemia produces very little 
degenerative changes. Ischaemia for 18 min resulted in an adverse outcome (2 deaths and 
4 animals requiring immediate euthanasia due to drastic weight loss and impaired 
movement).  
 
Neuron-specific nuclear protein (NeuN) immunoreactive neurones 
NeuN, a marker of mature neurons, was used to identify specifically the extent of neuronal 
death in the hippocampus (Figures 2A-B) and the cortex (Figures 2C-D). NeuN 
immunostained sections from BCCAO mice showed that 10 min ischaemia did not induce 
detectable loss of neurones in the examined area (cortex, hippocampus, stratum and 
thalamus) even after 7 days reperfusion. The numbers of NeuN-IR nuclei in the cerebral 
ischaemia group were dramatically decreased in specific regions of the cortex as well as the 
hippocampus when compared to the sham-operated group. Following 15min ischaemia and 
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7days reperfusion, cellular death was observed in the hippocampus (figure 2B) and the 
cortex (figure 2D) and to a lesser degree in the stratum and thalamus (data not shown). 
Quantitative analysis revealed that the numbers of NeuN positive cells were significantly 
(p<0.05) reduced in the CA1, CA2, CA3 areas of the hippocampus and the somatosensory 
and the motor areas of the cortex (figure 2E). 
 
Glial fibrillary acidic protein (GFAP) immunoreactivity  
Antibody to GFAP, a major protein constituent of glial filaments in differentiated astrocytes 
was used to identify glial cells. In the sham-operated animals, scattered GFAP-IR cells were 
distributed throughout the layers of the neocortex and in CA1, CA2, CA3 and dentate gyrus 
of the hippocampus. Substantial increases in the number and density of the GFAP 
immunopositive astroglial profiles, including enlarged cytoplasmic processes were found in 
the hippocampus (figure 3B) and the cortex (figure 3D) of the BCCAO mice following 15 min 
occlusion and 7 days reperfusion. Quantitative analysis of the GFAP-IR demonstrated that 
the cerebral ischaemia with 7 days reperfusion significantly increased the GFAP-IR astroglial 
profiles after the ischemic insult compared to the correspondent regions of the sham 
operated mice (figure 3E).  
 
Since both histochemical and immunohistochemical studies showed profound disrupted 
cellular changes in the cortex and the hippocampus visualised using both neuronal and glial 
markers following 15 min occlusion and 7 days reperfusion, the remainder of the results 
described below are based on observations in these animals.  
 
Glutamate synthetase (GS) immunoreactivity  
Antibodies to GS, the enzyme that converts glutamate to glutamine were used to examine 
the changes of this enzyme following ischaemia. GS-IR was confined to astrocyte cell 
bodies and processes and labelling was observed both in BCCAO and in sham operated 
animals. In sham operated animals, the glial cells had thin regular rims of GS positive 
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cytoplasm surrounding the nuclei in the hippocampal (figures 4A-B) and cortical regions 
(figure 4B, D). The extent and intensity of GS-IR both in the hippocampus (B) and the cortex 
(D) appeared to be changed with increased and redistributed IR profiles in BCCAO mice 
compared to sham operated group.  
 
Glial cells glutamate transporters (GLT1 and GLAST)  
Changes in glial glutamate transporter proteins induced by ischaemia were assessed by IHC 
using specific antibodies to GLT1 and GLAST. In brains of mice subjected to BCCAO, 
decreases in GLT1-IR with some irregular, disturbed and distorted morphology of the 
immunoreactive profiles were observed throughout the hippocampus (figures 4G-H) and the 
cortex (figures 4I-J) when compared to the sham-operated brains. There appeared to be 
some redistribution of GLAST-IR profiles within the hippocampus without any noticeable 
change in the intensity of immunoreactivity. Quantitative WB analysis with the same GLT1 
antibodies was used to verify the changes observed using IHC.  The results showed a 
significant decrease of GLT1 protein expression (***P< 0.001, N=6/ group) in the BCCAO 
brains as compared to the sham-operated brains (figures 4K - L).  
 
Vesicular glutamate transporters (VGLUT-1 and VGLUT-2) 
In the BCCAO mice a reduction in both VGLUT1 and VGLUT2 IRs compared to sham 
operated controls was observed in presumptive nerve terminals in the CA1 and CA2 sub-
regions of the hippocampus (figures 5A, B, E, F).  Figure 5B and D show the reduced 
VGLUT1 and VGLUT2 IRs respectively in the hippocampus CA1 areas.   In addition, the 
overall pattern of both VGLUT1 and VGLUT2 IR profiles appeared to be disrupted. 
WB analysis for VGLUT1 and VGLUT2 using the same antibodies showed significant 
reductions in both proteins in the hippocampus (figure 5C VGLUT1; **P<0.01, N=6/group), D 
VGLUT2; (***P<0.001, N= 6/ group) after cerebral ischaemia as compared to sham operated 
animals, thereby confirming the IHC results.  
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PHF1 tau protein  
To determine whether the observed immunohistochemical changes in glutamate 
transporters were associated with development of tau pathology we used anti-PHF1 for 
immunohistochemical and Western blot analysis. In the sham-operated animals, the pattern 
of immunostaining for PHF1 was consistent with few labelled profiles. We observed 
substantially increased intensity of PHF1–immunopositive structures in the hippocampus 
and cortex in the BCCAO mice.  Figures 6A-F shows characteristic staining using the anti-
PHF1 in the hippocampus both in sham and cerebral ischaemia animals.  
We used the same antibodies for WB analysis to quantify hyperphosphorylated tau protein 
expression in the hippocampus after ischemic insult. A significant increase of PHF1 
(***P<0.0001, t-test N= 6/group) was observed in ischemic hippocampus compared to the 
sham operated animals (figures 6G, H), consistent with the immunohistochemical 
observations.  
 
Memory correlates 
The same animals, in which glutamate transporter expression and tau pathology were 
subsequently investigated were subjected to the novel object recognition test, which 
evaluates non-spatial working memory. Significant impairment of performance in the novel 
object recognition test (*p<0.0006, N= 6/group) was observed after BCCAO, compared to 
the sham operated animals (figures 7A, B). 
 
Discussion 
The present study is the first systematic study investigating detailed neuronal and glial cell 
damage and changes in expression of both glial and synaptic glutamate transporter proteins 
in the cortex and the hippocampus following BCCAO and reperfusion in C57BL/6J mice.  It 
is also the first study to examine the expression of PHF1 tau protein in the hippocampus and 
correlated memory function in this model. 
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Several authors have used BCCAO in different strains of mice and reported that C57BL/6 
mice subjected to this technique developed selective neuronal death in the hippocampus, 
cortex and caudate putamen with better survival with this strain (Murakami et al., 1998; Yang 
et al., 1997).   However, very little information is available on detail pathological, biochemical 
and functional changes in this model.  Yang et al (1997) used seven mouse strains in their 
study and reported that the C57BL/6 strain was most susceptible to BCCAO, due to the poor 
development of the circle of Willis in this strain.   
 
Transient BCCAO causes selective vulnerability and neuronal death in several regions of the 
brain. Data from NeuN immunohistochemistry showed a selective loss of neurones in the 
CA1, CA2 and CA3 areas of the hippocampus and the cortex. Prominent neuronal damage 
was also observed in the motor, somatosensory and insular cortex. In addition, we 
investigated the changes in astrocytes following cerebral ischaemia injury. Astrocytes play a 
major role in the formation and maintenance of the brain cytoarchitecture and in addition to 
their structural and supportive roles they are involved in controlling synaptic function and 
maintaining the energy supply to neurones and recycling of neurotransmitters (Papa et al., 
2014).  Astrocytes, through their end feet, also cover and interact with endothelial cells of 
brain blood vessels and regulate the blood flow in the brain and control blood brain barrier. 
Following cerebral ischaemia injury induced by BCCAO, astrocytes processes, as identified 
by GFAP immunostaining, appeared to be rearranged and have become thicker, which is an 
indication of reactive gliosis, a reaction with specific structural and functional changes 
(Burda and Sofroniew , 2014; Papa et al., 2014; Pekny and Nilsson 2005). This may 
contribute to CNS circuit dysfunction, defining a maladaptive synaptic plasticity in the glial-
neuronal network leading to abnormal synaptic transmission (Papa et al., 2014).  
 
The present study also reports an increased expression of GS, an astrocyte-specific enzyme 
(Shaked et al., 2002) following ischaemic insult.  In support of this, it has been reported that 
activation of cultured cortical astrocytes by glutamate resulted in a prolonged increase of GS 
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expression in contrast to dramatic loss of glutamate transporter protein levels (Lehmann et 
al., 2009). However, we could not quantify this due to the lack of antibodies that were 
suitable for use in WB. 
 
We have evaluated expression of the major glial (GLT1 and GLAST) and synaptic glutamate 
transporter proteins (VGLUT1 and 2) in the cortex and the hippocampus after transient 
global ischaemia. When blood flow to the brain is compromised, neurones and glial cells are 
damaged through excessive activation of glutamate receptors (Flynn et al., 2008, Johnston, 
2005).  Because astrocytes maintain a high outwardly directed glutamate gradient across the 
cell membrane, activity of excitatory amino acid transporters in the cell membrane is highly 
dependent on cellular energy status to ensure efficient uptake of glutamate (Grewer and 
Rauen 2005).  Both GLAST and GLT1 are predominantly expressed by astrocytes (Sims and 
Robinson 1999) and effectively recycle glutamate back into neurones thereby preventing the 
build-up of excitotoxic levels of glutamate within the extracellular space (Anderson and 
Swanson 2000, Danbolt, 2001). 
 
We have earlier reported changes in hippocampal and cortical GLT1 but not GLAST 
following CI induced by transient middle cerebral artery occlusion in C57BL/6 mice 
(Ketheeswaranathan et al., 2011).  Transient global ischemia has been shown to 
downregulate glutamate transporter function of astrocytes obtained from the hippocampal 
CA1 region by decreasing mRNA and protein levels of GLT1 (Yeh et al., 2005).  The present 
study provides further evidence using both IHC and WB that transient CI downregulates 
GLT1 in the hippocampus. Our IHC study suggested some changes in GLAST-IR in the 
cortex and hippocampus but we could not quantify this due to the lack of suitable GLAST 
antibodies for WB.  
 
Our results suggest that expression levels of both VGLUT1 and VGLU2 were reduced 
significantly in the hippocampus. Changes in VGLUTs were previously reported in brain 
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ischaemia with variable results.  For example, VGLUT2 was downregulated in the CA1 
region of the gerbil hippocampus following transient global ischaemia (Iadecola, 2013) and in 
the rat cerebral cortex and caudate putamen following transient middle cerebral artery 
occlusion (Sánchez-Mendoza et al., 2010). The later study also reported the reduction of 
VGLUT1 protein level in the CA1 area of the hippocampus following 7 days after ischaemic 
insult in rats although these authors observed increased VGLUT1 following 3 days of 
ischaemia.  
 
Given that we observed a reduction in expression of both vesicular and cell membrane 
glutamate transporters, together with an apparent upregulation of GS in the hippocampus of 
mice subjected to BCCAO, we conclude that at least for the hippocampus, excitatory amino 
acid transporters may be compromised at all points in the glutamate-glutamine cycle. 
Vesicular glutamate transporters along with specific plasma glutamate transporters and GS 
may be potential targets for the prevention of excitotoxicity induced by ischemic stroke. 
Targeting to increase specific glutamate transporter activity in the brain may help to treat 
vascular diseases in the brain including stroke and vascular dementia.  
 
We have shown a significant increase in the PHF tau protein in the mouse hippocampus 
following cerebral ischaemic injury. This is in agreement with previously reported data 
indicating that PHF tau is increased in the hippocampus following BCCAO (Zhu et al., 2017). 
Tau phosphorylation is a key early event in the pathogenesis of neurodegenerative diseases 
including AD and vascular dementia. Tau is a microtubule-binding protein that contributes to 
the stability of microtubules when it is bound to polymerised tubulin.  The binding of tau 
protein to microtubules is reduced by increases in the phosphorylation state of tau and 
hyperphosphorylation of tau disrupts microtubules and interfere with inter-neuronal 
organelles leading to neuronal dysfunction, cellular death and memory loss (Clodfelder-
Miller et al, 2006; Johnson and Stoothoff 2004; Zhang et al., 2014). Our findings suggest 
that ischemic neuronal damage and glial cell activation are associated with increased PHF 
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tau. The exact mechanism involved in the structural cell damage that leads to or is 
associated with Tau pathology is not known. It is possible that reduced oxygen and glucose 
availability following chronic cerebral ischaemia insult results in less mitochondrial oxidative 
phosphorylation and production of optimal ATP levels for energy requiring processes in 
neurones and glial cells (Kalogeria et al., 2012; Watts et al., 2013).  
 
The results of the novel object recognition (NOR) behavioural assay, utilised to investigate 
the functional cognitive consequences of the BCCAO in these mice, demonstrated clear 
changes in novel object discriminatory ability. Experimentally occluded mice showed a 
significant reduction in the ability to discriminate a novel object which is indicative of memory 
deficits in this model of spatial and temporal memory (Ennaceur, 2010).  This result 
importantly translates a functional behavioural connection with those pathological changes 
found in the hippocampus as such behavioural changes are found in the NOR test following 
hippocampal insults (Clark et al., 2000). Further studies using this model are required to 
understand the underlying mechanisms of ischemia-induced memory impairment.  
 
In humans, however, it is difficult to distinguish between the cognitive deficits that occur in 
vascular dementia and Alzheimer’s disease due to the similarities in symptom presentation.  
Nevertheless, the deficits in the mice relate to memory as the novel object recognition task 
relies on intact memory or previously experienced objects and assesses the behavioural and 
neural processes mediating storage and/or recall of the features of the previously presented 
objects (Mumby D.G., 2001). The behavioural results showing a functional memory deficit 
because of the vascular occlusion in the present study suggests a relationship to vascular 
dementia. 
 
BCCAO models produce astrocytic and neuronal changes that closely resemble those that 
have been found in post mortem AD and vascular demented brains (Iadecola 2013; 
Serrano-Pozo et al., 2011) reinforcing the importance of this model for investigation of 
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neuronal and glial interaction in the tau pathology and memory dysfunction, raising the 
possibility of linking cerebral ischaemia and neurodegenerative diseases. The changes in 
tau protein in the human brain in vascular dementia are, however, not conclusive and 
changes in tau specifically in the hippocampus, as in our model, have not yet been 
reported.  An increase in the relative amount of PHF-1 and other phosphorylated tau species 
have been shown in the temporal and frontal cortices of patients with vascular dementia 
(Mukaetova-Ladinska et al., 2015) and neurofibrillary tangles (NFTs) of tau, including 
phosphorylated tau species, are reported as a common post-mortem finding in the human 
vascular dementia brain, although to a lesser degree than that seen in Alzheimer’s disease 
(Day et al., 2015). In addition, truncated tau species have also been identified in vascular 
dementia and have been suggested to be an early contributor to the formation of 
neurofibrillary tangles (Day et al., 2015). Changes in CSF total and phospho-tau have also 
been reported for vascular dementia indicating that changes in tau are significant in the 
disease (Skillback et al., 2015). While our data demonstrates an increase in PHF tau in our 
model, whether it is correlated with an increase in amyloid beta peptide remains to be 
determined.  
 
In conclusion, our results suggest that this optimised murine model of global cerebral 
ischaemia may be an ideal model to study cerebral ischaemia induced neurodegeneration 
and astrogliosis and open a new window for treatment of brain ischaemia and related 
diseases e.g., vascular dementia. Further studies on the interaction of glutamate 
transporters, GS and tau protein and their behavioural correlates in this model may allow us 
to find ideal targets to prevent those alterations that ultimately lead to neuronal death and 
onset of neurovascular disorders with major clinical impact.  
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Figure legends: 
Figure 1: Coronal sections through the hippocampus (A-H) and cerebral cortex (J-P) stained 
with Cresyl Violet in BCCAO and sham-operated mice. A & B show low power images of the 
hippocampus in sham-operated (A) and BCCAO (B) mice. Panels C-D, E-F and G-H show 
higher magnification images from, respectively CA1, CA2 and CA3 areas. Note the disrupted 
acidophilic neurones with evidence of small pyknotic cell nuclei in images D, F and H from 
BCCAO mice. I-P: Similar changes are observed in the motor cortex (I-L) and 
somatosensory cortex (M-P). 
Scale bars: A-B, I-J, M-N, 200µm; C-H, 50µm; K-L, O-P 25µm. 
 
Figure 2: NeuN-IR neurones on forebrain sections from sham-operated (A, C) and BCCAO 
(B, D) mice. In both the hippocampal CA1 (B) and the motor cortex (D) a disruption and loss 
of neurones with ischaemia is apparent. Scale bars 50µm.  
E: Quantitative analysis shows significant differences (P<0.001 ***, N= 6/group) in the 
number of NeuN-positive neurones between sham-operated and BCCAO mice in the 
somatosensory cortex (SS1) motor cortex (M1 and M2) and hippocampal CA1, CA2 and 
CA3 areas. 
 
Figure 3: GFAP-IR astrocytes on forebrain sections from sham-operated (A, C) and BCCAO 
(B, D) mice. In both the hippocampal CA1 (B) and the somatosensory cortex (D) an increase 
labelling of astrocytic processes indicative of reactive gliosis is apparent. Scale bars 50µm.  
E: Quantitative analysis shows significant increases (P<0.0001 *** and N=6/group) in the 
number of GFAP labelled astrocyte profiles in BCCAO mice compared to sham in the 
somatosensory cortex (SS1) motor cortex (M1 and M2) and hippocampal CA1, CA2 and 
CA3.  
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Figure 4: Immunolabelling of GS (A-D), GLAST (E-F) and GLT1 (G-J) in forebrain sections 
from sham-operated and BCCAO mice. Scale bars 50 µm. 
GS-IR in hippocampus CA1 appears upregulated in cell processes in BCCAO (B) as 
compared to sham-operated (A) brains. Similarly, GS expression in the motor cortex (D) 
appears upregulated in BCCAO mice. 
E-F: The distribution of GLAST-IR in the hippocampus appears similar in both sham-
operated (E) and BCCAO (F) mice. 
G-H; I-J: GLT1-IR is reduced in BCCAO compared to sham-operated mice in both 
hippocampus CA1 (G-H) and somatosensory cortex (I-J). 
K-L: WB analysis of GLT1 expression in hippocampus of sham-operated and BCCAO mice. 
K, band of approximately 60 KDa is greatly reduced in BCCAO compared to sham. L, 
quantitative analysis of GLT1 band density relative to ß-actin shows a significantly reduced 
expression in BCCAO mice (***P< 0.001, N=6/group).  
 
Figure 5: VGLUT1 and VGLUT2-IRs in the hippocampus of sham-operated and BCCAO 
mice. Scale bars 50 µm. 
A-D: The distribution of VGLUT1-IR puncta in CA1 appears reduced and disrupted in 
BCCAO (B) compared to sham (A). WB (C) reveals attenuated expression of VGLUT1 in the 
hippocampus after BCCAO as evidenced by the reduction in intensity of the band at 
approximately 47.5 KDa. Quantitative analysis (D) shows a significant reduction (**P<0.01, 
N=6/group) in VGLUT1 expression in BCCAO mice.  
E-H: Similarly, the VGLUT2-IR in CA1 show disrupted organisation in BCCAO (F) compared 
to sham (E). WB (G) and quantitative analysis (H) confirm significantly reduced (***P<0.001, 
N= 6/group) expression of VGLUT2 in BCCAO mice.  
 
Figure 6: Evidence for the development of tauopathy in the ischemic brain identified by 
antibody to PHF1. Prominent PHF1-IRs are found scattered throughout the hippocampus in 
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BCCAO mice (B, D), but this is not evident in sham-operated mice (A, C). Similarly, dense 
aggregations of PHF-1 IR are seen in the ischemic cortex in BCCAO mice (F) as compared 
to sham €. Scale bars 100 µm (A-B); 50 µm (C-F). 
G: WB demonstrates a lack of PHF1 signal in the hippocampus of sham-operated mice. H: 
Densitometric quantitative analysis shows a very significant increase (***P<0.0001, t-test N= 
6/group) in hyperphosphorylated tau with ischaemia in hippocampus of BCCAO mice.  
 
Figure 7: Memory function comparing sham-operated mice (Sham) vs mice with BCCAO. 
Discrimination ratio: (DR) = Tn/(Tn+Tf); Tf = Time with familiar object, Tn= Time with novel 
object. Significant impairment of performance in the novel object recognition test (*p<0.0006, 
N= 6/group) is observed in BCCAO mice compared to the sham-operated animals (B). 
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Table 1. Sources and Specifics of Antisera 
Primary/ 
secondary 
Antisera 
Species 
raised in  
Optimal 
dilution for 
IHC 
Optimal 
dilution for 
WB 
Raised and 
characterised by 
GLT-1 (B12) Rabbit 1/2000 1/3000 NC Danbolt 
(Lehre et al., 1995; 
Lehre and Danbolt, 
1998) 
GLAST (A522) Rabbit 1/2000 - NC Danbolt 
(Lehre et al., 1995; 
Lehre and Danbolt, 
1998) 
V-GluT-1  Rabbit 1/4000   1/1000 Jeffrey D. Erickson  
(Varoqui et al., 2002) 
V-GluT-2 Rabbit 1/4000   1/2000 Jeffrey D. Erickson  
(Varoqui et al., 2002) 
PHF Tau Mouse 1/1000 1/1000 Peter Davies 
Andorfer et al., 2003) 
NeuN  Mouse 1/5000 - Millipore, UK 
GFAP  Mouse 1/1000   - Sigma, UK 
GS  Mouse 1/1000 - Sigma, UK 
Biotinylated 
anti-mouse IgG  
Donkey 1/500 1/4000 Jackson, 
Immunoresearch, UK  
Biotinylated 
anti-mouse IgG 
Donkey 1/500 1/4000 Jackson 
Immunoresearch, UK 
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Highlights  
 
1. The present study optimised a murine model of global cerebral ischaemia which 
show consistent and selective neuronal and glial cell changes in the hippocampus 
and the cortex  
2. There are significant reduction in GLT1 (***P< 0.001), VGluT1 (**P<0.01) and 
VGluT2 (***P<0.001) expressions in the hippocampus in occluded mice as compared 
to sham-operated animals.  
3. There is a significant increase in PHF1 (***P<0.0001) protein in the hippocampus 
with a significant impairment of performance (*p<0.0006, N=6/group) in the novel 
object recognition test in ischaemic mice as compared to sham-operated mice.  
4. This model represents a useful tool for investigating cellular, biochemical and 
molecular mechanisms of global cerebral ischaemia and an ideal model for studying 
cerebral ischaemia induced vascular dementia.   
 
